Skip to main content

Table 1 Clinical situation of the 18 patients analysed in this study

From: The dosimetric impact of replacing the TG-43 algorithm by model based dose calculation for liver brachytherapy

Case index

Patient

Gender

Treated lesions

Diagnosis

pr. dose (Gy)

OARs

i

1

m

3

mCRC

25

esophagus, stomach

ii

2

m

4

HCC

15

bowel, esophagus, heart, kidney, stomach

iii

3

f

3

mCRC

25

bowel, kidney, stomach

iv

4

m

3

mCRC

25

bile duct, bowel, colon, stomach

v

4

m

1

mCRC

20

colon, duodenum, kidney, stomach

vi

5

m

2

HCC

12

colon, stomach

vii

6

m

1

HCC

15

heart, stomach

viii

7

m

1

HCC

12

bile duct, bowel, gall bladder, kidney

ix

8

m

1

mCRC

25

bile duct, colon, duodenum

x

8

m

1

mCRC

25

heart, oesophagus, stomach

xi

9

m

1

HCC

15

heart

xii

10

m

1

HCC

12

bowel, stomach

xiii

11

m

3

mCRC

20

bowel, duodenum, stomach

xiv

12

m

1

mCRC

25

colon, kidney

xv

13

m

1

mCRC

20

bowel, duodenum, stomach

xvi

14

m

5

mCRC

25

colon, duodenum, heart, stomach

xvii

15

f

3

mCRC

20

colon, stomach

xviii

16

m

3

HCC

15

heart

xix

17

m

2

mCRC

25

esophagus, heart, stomach

xx

18

f

1

mCRC

25

heart

  1. Patients 4 and 8 were treated twice with different treatment plans, so the total number of analysed cases was 20. Patients were diagnosed with either metastatic colorectal cancer (mCRC) or hepatocellular carcinoma (HCC). Prescription (pr.) doses ranged from 12 to 25 Gy. The last column lists the OARs which were considered for each case